Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.

Journal of neurology·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026
Same author

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Lancet (London, England)·2026
Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026
Same author

Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Advances in the management of pediatric low-grade glioma.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Natalizumab therapy for multiple sclerosis.

Jeremy Chataway1, David H Miller

  • 1Queen Square Multiple Sclerosis Centre, National Hospital for Neurology & Neurosurgery and University College London Institute of Neurology, Queen Square, London, WC1N 3BG, UK. jeremy.chataway@uclh.nhs.uk

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 12, 2013
PubMed
Summary
This summary is machine-generated.

Natalizumab, an anti-α4ß1 monoclonal antibody, has significantly advanced multiple sclerosis treatment since 1993. This review details its journey from research to clinical practice, exploring future oral therapies.

More Related Videos

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: May 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

  • Immunology and Neurology
  • Pharmacological Advancements in Neurodegenerative Diseases

Background:

  • The advent of ß-interferon in 1993 marked a turning point in treating relapsing-remitting multiple sclerosis (RRMS).
  • Natalizumab represents a significant therapeutic innovation in managing RRMS.

Purpose of the Study:

  • To review the developmental trajectory of natalizumab, a humanized anti-α4ß1 monoclonal antibody.
  • To examine natalizumab's progression from preclinical stages through clinical trials (Phase 1/2, Phase 3) to its current clinical application.
  • To discuss the future prospects and challenges associated with natalizumab and similar oral therapies.

Main Methods:

  • Review of preclinical research data.
  • Analysis of proof-of-concept (Phase 1/2) and pivotal (Phase 3) clinical trial outcomes.
  • Synthesis of extensive clinical practice experience with natalizumab.

Main Results:

  • Natalizumab has evolved from experimental research to a widely used treatment for RRMS.
  • Extensive clinical data support its efficacy and application in managing the condition.
  • The review highlights the transition of natalizumab through rigorous testing phases.

Conclusions:

  • Natalizumab has become a key therapeutic option in multiple sclerosis management.
  • Future research will focus on optimizing natalizumab use and developing novel oral therapies with similar mechanisms.